Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer

Inclusion Criteria: * Women with newly diagnosed human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor (ER) positive or negative, progesterone receptor (PR) positive or negative infiltrating ductal carcinoma (IDC) of the breast * Clinically stage II-III * Patients with inflammatory, multifocal, multicentric and synchronous bilateral breast cancers are allowed. However, in patients with inflammatory breast cancer, patients must have a measurable, biopsied mass within the breast pre-chemotherapy. * Willing and able to provide informed consent * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1 * Patients must be able to receive neoadjuvant anthracycline / taxane based chemotherapy in the opinion of the treating physician. Criteria include: * Adequate bone marrow function, as defined by peripheral granulocyte count of ≥ 1,500/mm3, and platelet count ≥100,000/mm3 * Adequate renal function with creatinine levels ≤ 1.5 X the upper limit of normal and estimated glomerular filtration rate (eGFR) \>30. * Adequate liver function with a bilirubin, Alkaline phosphatase and transaminases (ALT and AST) of ≤ 1.5 X the institutional upper limit of normal. * Multigated acquisition (MUGA) or echocardiogram (ECHO) demonstrating a left ventricular ejection fraction (LVEF) within institutional normal limits * Women of reproductive potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Patients may also co-enroll in trials that compare local therapies, or compare systemic adjuvant therapies. * Patients must have had (or be scheduled to have) a pre neoadjuvant chemotherapy MRI of the breast with gadolinium contrast as part of their planned routine breast cancer care. Exclusion Criteria: * Patients must not have had surgery or radiation or begun chemotherapy or endocrine therapy for their breast cancer prior to registration. * Patients must not be pregnant or nursing due to the possibility of harm to a fetus or nursing infant from this treatment regimen. * Presence of electrically, magnetically, or mechanically activated implants including cardiac pacemakers, cochlear implants, magnetic surgical clips or prosthesis that would preclude MRI. * History of severe claustrophobia * History of allergic reaction to gadolinium * Patients must not have metastatic disease * Baseline sensory/motor neuropathy \> grade 2 * Clinically significant cardiovascular disease * Serious intercurrent infection or nonmalignant medical illness * Creatinine clearance prohibiting the use of gadolinium (eGFR \< 30)